Leveraging RFID in hospitals: patient life cycle and mobility perspectives

The application of Radio Frequency Identification (RFID) to patient care in hospitals and healthcare facilities has only just begun to be accepted. This article develops a set of frameworks based on patient life cycle and time-and-motion perspectives for how RFID can be leveraged atop existing information systems to offer many benefits for patient care and hospital operations. It examines how patients are processed from admission to discharge, and considers where RFID can be applied. From a time-and-motion perspective, it shows how hospitals can apply RFID in three ways: fixed RFID readers interrogate mobile objects; mobile, handheld readers interrogate fixed objects; and mobile, handheld readers interrogate mobile objects. Implemented properly, RFID can significantly aid the medical staff in performing their duties. It can greatly reduce the need for manual entry of records, increase security for both patient and hospital, and reduce errors in administering medication. Hospitals are likely to encounter challenges, however, when integrating the technology into their day-to-day operations. What we present here can help hospital administrators determine where RFID can be deployed to add the most value

Effects of beliefs, motivation and entrepreneurial self-efficacy on entrepreneurial intentions: The moderating role of family support

Entrepreneurship is crucial for promoting innovation, creating employment opportunities and generating social and economic wealth in a country’s economy. In order to increase entrepreneurial activity, it is important to investigate entrepreneurial behavior by analyzing the process of businesses creation and the set of factors that favor the development of entrepreneurial aspirations, intentions and actions, which is a central goal ofpsychology of entrepreneurship. This research aims to deepen the knowledge about the relationship between the entrepreneurial self-efficacy, belief, motivation, family support and entrepreneurial intentions by developing a moderated mediation model. This study suggests that entrepreneurial self-efficacy partially mediates the effect of beliefs and motivations on entrepreneurial intention. This mediation is moderated by family support, which is also directly related to the intentions. The study was conducted on a sample of 446 students from four different high schools, and results support our hypotheses. Theoretical and practical implications from this research are further examined in the study

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis

We conducted a pooled analysis of two phase III trials, RV-MM-EMN-441 and EMN01, to compare maintenance with lenalidomide-prednisone vs. lenalidomide in newly diagnosed transplant-eligible and -ineligible myeloma patients. Primary endpoints were progression-free survival, progression-free survival 2 and overall survival with both regimens. A secondary aim was to evaluate the impact of duration of maintenance on overall survival and on outcome after relapse. A total of 625 patients (lenalidomide-prednisone arm, n = 315; lenalidomide arm, n = 310) were analyzed. The median follow-up was 58 months. Median progression-free survival (25 vs. 19 months; p = 0.08), progression-free survival 2 (56 vs. 49 months; p = 0.9) and overall survival (73 months vs. NR; p = 0.08) were not significantly different between the two arms. Toxicity profiles of lenalidomide-prednisone and lenalidomide were similar, with the exception of neutropenia that was higher in the lenalidomide arm (grade ≥ 3: 9% vs. 19%, p < 0.001), without an increase in the rate of infections. Overall survival (median NR vs. 49 months, p < 0.001), progression-free survival from relapse (median 35 vs. 24 months, p = 0.004) and overall survival from relapse (median not reached vs. 41 months, p = 0.002) were significantly longer in patients continuing maintenance for ≥2 years. We showed that the addition of prednisone at 25 or 50 mg every other day (eod) to lenalidomide maintenance did not induce any significant advantage

Radiation Hardened Architecture of a Single-Ended Raman-Based Distributed Temperature Sensor

Raman-based Distributed Temperature Sensors (RDTS) allow performing spatially resolved (1 m) reliable temperature measurements over several km long Optical Fibers (OFs). These systems are based on the temperature dependence of the intensities of both the Stokes and anti-Stokes components of the Raman back-scattered signal. One of the specific issues associated with RDTS technology in radiation environments is the differential Radiation Induced Attenuation (RIA) between the two components that induces huge errors in the temperature evaluation. Such problem is particularly evident for commercially available single-ended DTS using one laser source. Double-ended configuration could be used to correct for the differential attenuation but are limited by RIA in terms of sensing range. In the present work, we show how a Radiation-Hardened-by-Design DTS (RHD-DTS) overcomes the observed radiation issues keeping the single-ended interrogation scheme. In the tested RHD-DTS two infrared excitation laser sources (~1550 nm and ~1650 nm) are employed: the wavelength of the Stokes component due to the first excitation source coincides with the wavelength of the second excitation; vice versa, the wavelength of the anti-Stokes component due to the second excitation source coincides with the wavelength of the first excitation. The overall result is that the two signal intensities are automatically corrected for the differential RIA all along the OF sensor length and the temperature measurements becomes robust against radiation effects. This study demonstrates the potential of such a sensor by reporting preliminary experimental results obtained with a prototype developed by Viavi Solutions exploiting radiation-sensitive or radiation-hardened optical fibers

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials

The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis–therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P &lt; 0.0001), older age (HR = 1.72; P &lt; 0.0001), and prior lenalidomide exposure (HR = 1.30; P = 0.026) remained independently associated with death. The median PFS was 20.3 months, with no difference between the two strategies. The multivariate model identified a significant progression/death risk increase for ISS III (HR = 1.37; P = 0.002), &gt;3 previous lines of therapies (HR = 1.67; P &lt; 0.0001), older age (HR = 1.64; P &lt; 0.0001), and prior lenalidomide exposure (HR = 1.35; P = 0.003). Three risk SRSKRd/EloRd categories were generated: low-risk (134 cases, 16.5%), intermediate-risk (467 cases, 57.3%), and high-risk categories (213 cases, 26.2%). The 1- and 2-year OS probability rates were 92.3% and 83.8% for the low-risk (HR = 1, reference category), 81.1% and 60.6% (HR = 2.73; P &lt; 0.0001) for the intermediate-risk, and 65.5% and 42.5% (HR = 4.91; P &lt; 0.0001) for the high-risk groups, respectively. Notably, unlike the low-risk group, which did not cross the median timeline, the OS median values were 36.6 and 18.6 months for the intermediate- and high-risk cases, respectively. Similarly, three PRSKRd/EloRd risk categories were engendered. Based on such grouping, 338 (41.5%) cases were allocated in the low-, 248 (30.5%) in the intermediate-, and 228 (28.0%) in the high-risk groups. The 1- and 2-year PFS probability rates were 71.4% and 54.5% for the low-risk (HR = 1, reference category), 68.9% and 43.7% (HR = 1.95; P &lt; 0.0001) for the intermediate-risk, and 48.0% and 27.1% (HR = 3.73; P &lt; 0.0001) for the high-risk groups, respectively. The PFS median values were 29.0, 21.0, and 11.7 months for the low-, intermediate-, and high-risk cases. This analysis showed 2.7- and 4.9-fold increased risk of death for the intermediate- and high-risk cases treated with KRd/EloRd as salvage therapy. The combined progression/death risks of the two categories were increased 1.3- and 2.2-fold compared to the low-risk group. In conclusion, SRSKRd/EloRd and PRSKRd/EloRd may represent accessible and globally applicable models in daily clinical practice and ultimately represent a prognostic tool for RRMM patients who received KRd or EloRd